Evolution of the susceptibility to antiviral drugs of A/H3N2 influenza viruses isolated in France from 2002 to 2005

Vaccine

Volumn 24, Issue 44-46, 2006, Pages 6656-6659

  Ferraris, Olivier ^a   Kessler, Nicole ^a   Valette, Martine ^a   Lina, Bruno ^a  

^a Ctr Natl de Ref pour la Grippe   (France)

Author keywords

Influenza; Inhibitors; Neuraminidase deficient

Indexed keywords

ANTIVIRUS AGENT; GLYCOPROTEIN; OSELTAMIVIR; VIRUS SIALIDASE; ZANAMIVIR;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG SENSITIVITY; ENZYME ACTIVITY; EVOLUTION; FRANCE; GENE MUTATION; IC 50; INFLUENZA VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; VIRUS CULTURE; VIRUS ISOLATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; EVOLUTION, MOLECULAR; FRANCE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INHIBITORY CONCENTRATION 50; NEURAMINIDASE; OSELTAMIVIR; ZANAMIVIR;

EID: 33846343627     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.05.050     Document Type: Article

References (8)

1. Von Itzstein M., Wu W.Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363 (1993) 418-423
2. Li W., Escarpe P.A., Eisenberg E.J., Cundy K.C., Sweet C., Jakeman K.J., et al. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42 (1998) 647-653
3. Lina B., Valette M., Foray S., Luciani J., Stagnara J., See D.M., et al. Surveillance of community-acquired viral infections due to respiratory viruses in Rhone-Alpes (France) during winter 1994-1995. J Clin Microbiol 34 (1996) 3007-3011
4. Aymard-Henry M., Coleman M.T., Dower R., Laver W.G., Schild G.C., and Webster R.G. Influenza virus neuraminidase and neuraminidase-inhibition test procedure. Bull WHO 48 (1973) 199-202
5. Ferraris O., Kessler N., and Lina B. Sensitivity of influenza viruses to zanamivir and oseltamivir: A study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res 68 1 (2005) 43-48
6. Liu C., Eichelberger M.C., Compans R.W., and Air G.M. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol 69 2 (1995) 1099-1106
7. Hughes M.T., Matrosovich M., Rodgers M.E., McGregor M., and Kawaoka Y. Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice. J Virol 74 11 (2000) 5206-5212
8. Gubareva L.V., Nedyalkova M.S., Novikov D.V., Murti K.G., Hoffmann E., and Hayden F.G. A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site. J Gen Virol 83 11 (2002) 2683-2692